Print

Arena Pharmaceuticals, Inc. (ARNA) to Present at Upcoming Investor Conferences  
8/31/2012 9:16:34 AM

SAN DIEGO, Aug. 30, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announcedtoday that the company is scheduled to present corporate updates at the following three upcoming investor conferences:

  • Stifel Nicolaus Healthcare Conference
    Presentation: September 6, 2012, at 9:10 a.m. Eastern Time (6:10 a.m. Pacific Time) at the Four Seasons Hotel in Boston, Massachusetts
    Presenting: Robert E. Hoffman, Senior Vice President, Finance and Chief Financial Officer
  • NewsMakers in the Biotech Industry
    Presentation: September 7, 2012, at 10:30 a.m. Eastern Time (7:30 a.m. Pacific Time) at the Millennium Broadway Hotel in New York, New York
    Presenting: Craig M. Audet, Senior Vice President, Operations and Head of Global Regulatory Affairs
  • Bank of America Merrill Lynch Global Healthcare Conference
    Presentation: September 12, 2012, at 8:55 a.m. British Summer Time (12:55 a.m. Pacific Time) at the Bank of America Merrill Lynch Financial Centre in London, England
    Presenting: Dominic P. Behan, Ph.D., Executive Vice President and Chief Scientific Officer

Arena's presentations at these conferences will be webcast live. Each of the audio webcasts will be available under the investor relations section of Arena's website at www.arenapharm.com, and will be archived there for 30 days following the presentation. Please connect to Arena's website several minutes prior to the start of each webcast to ensure adequate time for any software download that may be necessary.

Arena also announced today that it is scheduled to participate in panel presentations at Citi's 7th Annual Biotech Day on September 5, 2012, at the Mandarin Oriental Hotel in Boston, Massachusetts and at the Rodman and Renshaw Global Investment Conference on September 10, 2012, at The Waldorf Astoria Hotel in New York, New York. These panel presentations will not be webcast.

About Arena Pharmaceuticals
Arena Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel drugs for weight management, cardiovascular disease, inflammation and other disorders. Arena's US operations are located in San Diego, California, and its operations outside of the United States, including its commercial manufacturing facility, are located in Zofingen, Switzerland. For more information about Arena, please visit www.arenapharm.com.

Arena Pharmaceuticals® and Arena® are registered service marks of Arena Pharmaceuticals, Inc.

Forward-Looking Statements
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's efforts, focus, goals, strategy, research and development programs, and ability to discover and develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: risks related to commercializing drugs, including regulatory, manufacturing and supply issues and the pace of market acceptance; cash and revenues generated from lorcaserin, including the timing and impact of competition; the timing and outcome of regulatory review is uncertain; government and commercial reimbursement and pricing decisions; risks related to relying on collaborative agreements; the timing and receipt of payments and fees, if any, from collaborators; the entry into, modification or termination of collaborative arrangements; unexpected or unfavorable new data; nonclinical and clinical data is voluminous and detailed, and regulatory agencies may interpret or weigh the importance of data differently and reach different conclusions than Arena, request additional information, have additional recommendations or change their guidance or requirements before or after approval; data and other information related to any of Arena's research and development programs may not meet safety, efficacy or other regulatory requirements or otherwise be sufficient for regulatory review, approval or continued marketing; Arena's ability to obtain and defend patents; the timing, success and cost of Arena's research and development programs; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner expected or at all; having adequate funds; and satisfactory resolution of litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Contact: Arena Pharmaceuticals, Inc.

Media Contact: Russo Partners



Cindy McGee, Vice President,

David Schull, President

Investor Relations & Alliance Management

david.schull@russopartnersllc.com

cmcgee@arenapharm.com

858.717.2310

858.453.7200, ext. 1479




www.arenapharm.com


SOURCE Arena Pharmaceuticals, Inc.


//-->